FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
Summary: FibroBiologics has successfully manufactured and released the first clinical batch of CYWC628, its novel fibroblast-based spheroid therapeutic candidate. This milestone enables the start of patient enrollment in the Phase 1/2 clinical trial for diabetic foot ulcers (DFU). The company aims to leverage the regenerative potential of fibroblasts to improve healing in chronic, hard-to-heal DFUs.
Key Highlights:
- First GMP batch of CYWC628 released and ready for clinical use
- Phase 1/2 DFU trial imminent with patient dosing expected soon
- Novel spheroid technology targeting regenerative wound repair
- Part of FibroBiologics’ broader regenerative medicine platform
Keywords: CYWC628, FibroBiologics DFU, fibroblast spheroid